Larimar Therapeutics (LRMR) Leerink’s Global Healthcare Conference 2025 summary

Clinical development updates

• Three studies completed: SAD, MAD, and dose exploration, with an ongoing open label extension and adolescent study; all patients now on 50 mg dose.

• 25 mg dose achieves near 50% of healthy frataxin levels in many patients; 50 mg dose expected to get 60% of patients above 50% of normal, with minimal risk of exceeding 100%.

• Adolescent cohort (12–17 years) dosing began in January; after PK confirmation, a cohort for ages 2–11 is planned.

• Mid-2025 data release will include PK, frataxin, and long-term safety data, with patient numbers exceeding previous releases.

• Clinical outcomes focus on upper limb dexterity and natural history comparisons, especially in non-ambulatory and pediatric patients.

Regulatory and approval strategy

• Engaged in ongoing dialogue with FDA and EMA, aiming for accelerated approval using frataxin as a surrogate endpoint.

• FDA receptive to animal data supporting frataxin increases as reasonably likely to predict clinical benefit; human data not strictly required.

• Confirmatory study to enroll 100–150 ambulatory patients, likely starting mid-year, with endpoints under discussion (upright stability or mFARS).

• BLA filing targeted for the second half of the year, with patient exposure expected to be typical for rare diseases.

• Safety database requirements and confirmatory study protocol being finalized with regulators.

Competitive landscape and positioning

• Product targets the root cause of disease by replacing deficient frataxin, differentiating from other approved and pipeline therapies.

• Early intervention, especially in pediatric patients, seen as a key advantage for preventing disease progression.

• Combination therapy is a topic among KOLs, but payer acceptance is uncertain; product may be best suited for early-stage intervention.